MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$12,227K
Free Cash flow
$15,386K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation expense
Proceeds from maturities of mark...
Other receivables
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net income (loss)
Other noncurrent assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-17,931
-13,470
-16,252
-27,472
Stock-based compensation expense
25,616
22,642
25,219
25,264
Depreciation and amortization
9,664
9,957
10,065
10,297
Rou assets impairment due to restructuring
-
-
1,253
-
Amortization of right-of-use assets
-
-
2,035
1,954
Non-cash lease expense
2,016
1,953
-
-
Fair value adjustments on contingent consideration
-3,523
57
-272
-1,135
Asset and lease impairment charges
0
0
0
700
Realized loss on marketable securities
-
-
0
0
Deferred income taxes
-1,434
-
-
-
Other
-423
-193
-393
-434
Accounts receivable
8,514
-7,980
3,232
-6,629
Other receivables
-14,018
-18,129
-17,334
-16,276
Inventory
-3,001
-2,702
-5,582
-7,287
Prepaid expenses and other current assets
-1,206
-1,945
2,985
-1,383
Other noncurrent assets
12,205
-282
1,601
149
Accounts payable
3,290
4,782
-5,418
-196
Accrued compensation and other related benefits
3,123
-20,956
5,363
10,101
Deferred revenue
-1,586
77
1,394
-190
Accrued contingent consideration and assumed liabilities
0
-613
-
-
Accrued expenses and other current liabilities
-3,558
-6,136
4,786
-7,048
Operating lease liability
-2,972
-2,854
-2,720
-2,604
Other noncurrent liabilities
140
-50
75
281
Net cash provided by operating activities
16,974
26,120
40,777
43,214
Purchase of intangible assets
-
-
0
0
Asset acquisition, net
-
-
652
8,616
Business combination
6,101
-
-
-
Proceeds from sales of marketable securities
-
-
0
0
Purchases of property and equipment
1,588
1,597
1,777
687
Purchases of marketable securities
24,546
24,714
24,576
49,498
Proceeds from maturities of marketable securities
25,000
25,000
25,200
50,000
Purchase of equity interest rights
500
-
-
-
Net cash used in investing activities
-7,735
-1,311
-1,805
-8,801
Issuance of common stock from exercise of stock options
3,016
273
2,242
617
Payments on technology license financing arrangement
-
-
0
-
Payment of contingent consideration
0
8,690
-
-
Net cash provided by (used in) financing activities
3,016
-8,417
2,242
617
Effect of exchange rates changes on cash and cash equivalents
-28
-73
43
-33
Net increase in cash and cash equivalents
12,227
16,319
41,257
34,997
Cash and cash equivalents at beginning of period
490,285
473,966
432,709
344,067
Cash and cash equivalents at end of period
502,512
490,285
473,966
432,709
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Stock-based compensation
expense
$25,616K
(-56.31%↓ Y/Y)
Issuance of common stock
from exercise of...
$3,016K
(-23.53%↓ Y/Y)
Other receivables
-$14,018K
(-120.47%↓ Y/Y)
Depreciation and
amortization
$9,664K
(-38.98%↓ Y/Y)
Fair value
adjustments on contingent...
-$3,523K
Accounts payable
$3,290K
(-5.68%↓ Y/Y)
Accrued compensation
and other related...
$3,123K
(139.95%↑ Y/Y)
Inventory
-$3,001K
(80.10%↑ Y/Y)
Non-cash lease expense
$2,016K
Prepaid expenses and
other current assets
-$1,206K
(-262.75%↓ Y/Y)
Other noncurrent
liabilities
$140K
(-86.54%↓ Y/Y)
Net cash provided by
operating activities
$16,974K
(-67.39%↓ Y/Y)
Net cash provided by
(used in) financing...
$3,016K
(-23.53%↓ Y/Y)
Canceled cashflow
$48,623K
Net increase in cash
and cash...
$12,227K
(-77.21%↓ Y/Y)
Canceled cashflow
$7,763K
Net income (loss)
-$17,931K
(-10061.67%↓ Y/Y)
Other noncurrent
assets
$12,205K
(600.41%↑ Y/Y)
Accounts receivable
$8,514K
(122.45%↑ Y/Y)
Accrued expenses and
other current...
-$3,558K
(-23.07%↓ Y/Y)
Operating lease liability
-$2,972K
(40.39%↑ Y/Y)
Deferred revenue
-$1,586K
(-246.29%↓ Y/Y)
Deferred income taxes
-$1,434K
Other
-$423K
(54.32%↑ Y/Y)
Proceeds from maturities
of marketable...
$25,000K
(-50.00%↓ Y/Y)
Net cash used in
investing activities
-$7,735K
(-173.13%↓ Y/Y)
Effect of exchange
rates changes on cash...
-$28K
(-105.91%↓ Y/Y)
Canceled cashflow
$25,000K
Purchases of marketable
securities
$24,546K
(-50.27%↓ Y/Y)
Business combination
$6,101K
Purchases of property and
equipment
$1,588K
(-54.25%↓ Y/Y)
Purchase of equity
interest rights
$500K
Buy us a coffee
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)